HK Innoen Receives Product Approval for K-CAB Tablets in the Philippines

[Asia Economy Reporter Junho Hwang] HK inno.N announced on the 23rd that it has received product approval for K-CAB tablets in the Philippines from the Philippine Food and Drug Administration.

The company stated, "With the acquisition of local product approval for K-CAB tablets (tegoprazan), a treatment for gastroesophageal reflux disease, starting from the Philippines, we will actively enter the Southeast Asian market and contribute to the expansion of overseas sales."

It added, "K-CAB tablets (tegoprazan) are drugs with a P-CAB (Potassium-competitive acid blocker) mechanism that reversibly block proton pumps responsible for secreting gastric acid in the stomach lining, thereby suppressing acid secretion," and "they show faster and more sustained effects compared to drugs with a PPI (Proton Pump Inhibitor) mechanism."